Stock listing
Frankfurt:12V Veracyte, Inc. Aktie
German listing (Frankfurt) of Veracyte, Inc. · home listing NASDAQ:VCYT
Follow Veracyte, Inc. into a list and get an email when it puts out news.
Share price · FWB:12V
€22.29 EUR -1.12 (-4.8%)
Close on Nov 20, 2026
- Day range
- €22.29 – €22.29 EURNov 20, 2026
- Market cap
- €1.80B EURAt the close on Nov 20, 2026 · price × 80.70M shares outstanding
- 52-week range
- €21.22 – €52.45 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €2,350 EURMedian day 0 shares · 34 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VCYT · Home | $25.13 USD | -0.44 (-1.7%) | 2,792,810 | $24.63 | $25.60 | $24.53 | $25.57 | Close on Nov 20, 2026 |
| Frankfurt:12V | €22.29 EUR | -1.12 (-4.8%) | — | €22.29 | €22.29 | €22.29 | €23.41 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:12V · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €21.29 | -0.096 | -0.4% | €21.29 | €21.29 | €21.29 | 1,270 | |
| €21.39 | -23.33 | -52.2% | €33.45 | €34.64 | €21.22 | 137 | |
| €44.72 | +1.507 | +3.5% | €44.36 | €45.18 | €44.18 | 137 | |
| €43.21 | -1.356 | -3.0% | €43.21 | €43.21 | €43.21 | 0 | |
| €44.57 | -0.878 | -1.9% | €44.57 | €44.57 | €44.57 | 0 | |
| €45.45 | +0.231 | +0.5% | €45.45 | €45.45 | €45.45 | 120 | |
| €45.22 | +0.107 | +0.2% | €44.68 | €45.69 | €44.65 | 46 | |
| €45.11 | -0.217 | -0.5% | €45.11 | €45.11 | €45.11 | 700 | |
| €45.33 | +2.553 | +6.0% | €42.52 | €45.42 | €42.19 | 59 | |
| €42.77 | +2.887 | +7.2% | €42.43 | €42.81 | €42.43 | 108 | |
| €39.89 | +0.256 | +0.6% | €40.15 | €40.83 | €39.83 | 126 | |
| €39.63 | +0.317 | +0.8% | €39.63 | €39.63 | €39.63 | 0 | |
| €39.31 | +1.053 | +2.8% | €39.31 | €39.31 | €39.31 | 0 | |
| €38.26 | -0.991 | -2.5% | €38.26 | €38.26 | €38.26 | 0 | |
| €39.25 | +0.411 | +1.1% | €38.76 | €39.26 | €38.59 | 100 | |
| €38.84 | +1.307 | +3.5% | €38.84 | €38.84 | €38.84 | 0 | |
| €37.53 | -0.302 | -0.8% | €37.53 | €37.53 | €37.53 | 0 | |
| €37.84 | -0.746 | -1.9% | €37.84 | €37.84 | €37.84 | 0 | |
| €38.58 | -1.084 | -2.7% | €38.58 | €38.58 | €38.58 | 0 | |
| €39.67 | +1.055 | +2.7% | €39.88 | €39.98 | €39.55 | 10 | |
| €38.61 | +0.637 | +1.7% | €38.61 | €38.61 | €38.61 | 200 | |
| €37.97 | -1.295 | -3.3% | €37.97 | €37.97 | €37.97 | 48 | |
| €39.27 | -3.801 | -8.8% | €39.27 | €39.27 | €39.27 | 0 | |
| €43.07 | +2.828 | +7.0% | €42.52 | €43.18 | €42.25 | 59 | |
| €40.24 | +1.599 | +4.1% | €40.24 | €40.24 | €40.24 | 0 | |
| €38.64 | -2.656 | -6.4% | €38.64 | €38.64 | €38.64 | 0 | |
| €41.30 | +0.378 | +0.9% | €40.68 | €41.30 | €40.63 | 120 | |
| €40.92 | +1.87 | +4.8% | €40.44 | €41.02 | €40.44 | 149 | |
| €39.05 | +0.113 | +0.3% | €39.05 | €39.05 | €39.05 | 0 | |
| €38.94 | -2.997 | -7.1% | €38.94 | €38.94 | €38.94 | 0 | |
| €41.93 | +4.177 | +11.1% | €41.93 | €41.93 | €41.93 | 72 | |
| €37.76 | +0.566 | +1.5% | €37.76 | €37.76 | €37.76 | 0 | |
| €37.19 | +1.861 | +5.3% | €37.19 | €37.19 | €37.19 | 0 | |
| €35.33 | -0.043 | -0.1% | €35.33 | €35.33 | €35.33 | 0 | |
| €35.37 | +0.61 | +1.8% | €34.40 | €35.80 | €34.16 | 84 | |
| €34.76 | +1.811 | +5.5% | €34.76 | €34.76 | €34.76 | 0 | |
| €32.95 | -1.504 | -4.4% | €32.95 | €32.95 | €32.95 | 0 | |
| €34.46 | -0.736 | -2.1% | €34.46 | €34.46 | €34.46 | 0 | |
| €35.19 | +0.862 | +2.5% | €35.19 | €35.19 | €35.19 | 0 | |
| €34.33 | -1.288 | -3.6% | €34.33 | €34.33 | €34.33 | 0 | |
| €35.62 | -1.519 | -4.1% | €35.62 | €35.62 | €35.62 | 0 | |
| €37.14 | +0.919 | +2.5% | €37.14 | €37.14 | €37.14 | 0 | |
| €36.22 | +0.362 | +1.0% | €36.22 | €36.22 | €36.22 | 0 | |
| €35.86 | -0.939 | -2.6% | €35.86 | €35.86 | €35.86 | 0 | |
| €36.80 | -1.195 | -3.1% | €36.44 | €37.30 | €36.40 | 60 | |
| €37.99 | -0.343 | -0.9% | €37.99 | €37.99 | €37.99 | 50 | |
| €38.33 | +1.742 | +4.8% | €38.29 | €38.34 | €38.25 | 10 | |
| €36.59 | -0.263 | -0.7% | €36.59 | €36.59 | €36.59 | 0 | |
| €36.85 | +0.376 | +1.0% | €36.85 | €36.85 | €36.85 | 0 | |
| €36.48 | -1.776 | -4.6% | €36.48 | €36.48 | €36.48 | 0 | |
| €38.25 | +0.53 | +1.4% | €38.25 | €38.25 | €38.25 | 60 | |
| €37.72 | +0.433 | +1.2% | €37.72 | €37.72 | €37.72 | 0 | |
| €37.29 | +2.056 | +5.8% | €37.29 | €37.29 | €37.29 | 0 | |
| €35.24 | -0.475 | -1.3% | €35.24 | €35.24 | €35.24 | 0 | |
| €35.71 | +0.531 | +1.5% | €35.71 | €35.71 | €35.71 | 0 | |
| €35.18 | -0.371 | -1.0% | €35.18 | €35.18 | €35.18 | 176 | |
| €35.55 | +1.216 | +3.5% | €35.55 | €35.55 | €35.55 | 0 |
- Ticker
- Frankfurt:12V
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Veracyte Announces Third Quarter 2026 Financial Results
Latest earnings call · Nov 4, 2026
Veracyte (NASDAQ:VCYT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jul 30, 2026
Q2 2026 Earnings Presentation
Earnings · 23 slides
Latest news
Veracyte Announces Third Quarter 2026 Financial Results
Nov 4, 2026
Closed €21.39 (-52.2%) on Nov 5, 2026
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026
Nov 2, 2026
Closed €44.57 (-1.9%) on Nov 2, 2026
Veracyte to Participate in Upcoming Investor Conferences
Oct 29, 2026
Closed €45.45 (+0.5%) on Oct 30, 2026
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Oct 23, 2026
Closed €39.89 (+0.6%) on Oct 23, 2026
Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Oct 19, 2026
Closed €39.25 (+1.1%) on Oct 19, 2026
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Oct 16, 2026
Closed €38.84 (+3.5%) on Oct 16, 2026
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Oct 14, 2026
Closed €37.53 (-0.8%) on Oct 15, 2026
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Sep 29, 2026
Closed €39.05 (+0.3%) on Sep 29, 2026
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Sep 25, 2026
Closed €38.94 (-7.1%) on Sep 28, 2026
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Sep 14, 2026
Closed €35.19 (+2.5%) on Sep 15, 2026
Veracyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 27 in the last 12 months · 261 in all · newest Nov 4, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 4, 2026
- Decks
- 19 decks · latest Jul 30, 2026
Where Veracyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VCYT · Home listing | NASDAQ | United States | USD |
| gettex:12V | gettex | Germany | EUR |
| BOATS:VCYT | BOATS | United States | USD |
| LS Exchange:A1W7EA | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1W7EA | Lang & Schwarz | Germany | EUR |
| Tradegate:12V | Tradegate | Germany | EUR |
| Dusseldorf:12V | Dusseldorf | Germany | EUR |
| Frankfurt:12V · This page | Frankfurt | Germany | EUR |
| Munich:12V | Munich | Germany | EUR |
| Hamburg:12V | Hamburg | Germany | EUR |
| Stuttgart:12V | Stuttgart | Germany | EUR |
Valuation
P/E 16.0× against a median of 58.0×: the lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.70B USD
- P/E
- 16.0×
- EV/sales
- 2.9×
- EV/EBITDA
- 14.0×
- Price/book
- 1.4×
- Gross margin
- 72.0%
- Operating margin
- 17.1%
- Net margin
- 21.8%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.34
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Veracyte, Inc. · NASDAQ:VCYT | US$2.03B | US$1.70B | 16.0× | 2.9× | 14.0× | 1.4× | 21.8% | 0.0× | 1.34 |
| Oxford Nanopore Technologies PLC · LSE:ONT | US$2.42B | US$2.23B | n/a | 7.6× | n/a | 4.4× | −64.8% | 0.1× | n/a |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.97B | US$1.77B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| Median of the others | US$1.93B | US$1.83B | 58.0× | 7.9× | 40.6× | 4.0× | 2.4% | 0.1× | 1.68 |
Forecasts
7 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 41.60 USD · Analysts' mean
- EPS, year to Dec 2026
- 1.94 · 10 analysts
- Revenue, year to Dec 2026
- 590.8M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Stapley | Chief Executive Officer |
| Kevin Haas | Chief Development and Technology Officer |
Board
| Director | Role |
|---|---|
| Robert S. Epstein | Chairman |
| Brent Shafer | Board Member |
| Eliav Barr | Board Member |
| Evan Jones | Board Member |
| Jens Holstein | Board Member |
| Karin Eastham | Board Member |
| Muna Bhanji | Board Member |
| Tom Miller |
Events
Calls
| Call | When | Status |
|---|---|---|
| Veracyte (NASDAQ:VCYT) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q1 2026 Earnings Call | Tue, May 05, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q3 2025 Earnings Call | Tue, Nov 04, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q4 2024 Earnings Call | Mon, Feb 24, 2025 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| Veracyte (NASDAQ:VCYT) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −54.3% |
| Q2 2026 | Jul 30, 2026 · After close | −22.5% |
| Q1 2026 | May 5, 2026 · After close | +24.9% |
| Q4 2025 | Feb 25, 2026 | +8.6% |
| Q3 2025 | Nov 4, 2025 · After close | +27.5% |
| Q2 2025 | Aug 6, 2025 · After close | +15.5% |
| Q1 2025 | May 7, 2025 · After close | +1.2% |
| Q4 2024 | Feb 20, 2025 · Before open | −2.5% |
| Q3 2024 | Nov 6, 2024 · After close | +2.0% |
| Q2 2024 | Aug 6, 2024 · After close | +24.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −4.3% |
| Q4 2023 | Feb 22, 2024 · After close | −8.9% |
| Q3 2023 | Nov 7, 2023 · After close | −3.6% |
| Q2 2023 | Aug 8, 2023 · After close | +7.0% |
| Q1 2023 | May 4, 2023 · After close | +4.6% |
| Q4 2022 | Feb 22, 2023 · After close | +0.1% |
| Q3 2022 | Nov 2, 2022 · After close | +24.3% |
| Q2 2022 | Aug 2, 2022 · After close | −6.0% |
| Q1 2022 | May 3, 2022 · After close | +4.6% |
| Q4 2021 | Feb 28, 2022 · After close | +0.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Jul 30, 2026 |
| Investor Presentation (June 2026) | Investor deck | 20 slides | Jun 1, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 22 slides | May 5, 2026 |
| Raymond James Institutional Investor Conference 2026 | Conference | 33 slides | March 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 25, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | Nov 4, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 24 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 26 slides | Feb 24, 2025 |
| Q2 2024 Earnings Presentation | Earnings | 15 slides | Aug 6, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 16 slides | May 7, 2024 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2023 Earnings Presentation | Earnings | 16 slides | Feb 22, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 17 slides | Nov 7, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 17 slides | Aug 8, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 17 slides | May 4, 2023 |
| Q1 2022 Earnings Presentation | Earnings | 15 slides | May 3, 2022 |
| Merger or Acquisition (February 2021) | Merger or acquisition | 18 slides | Feb 3, 2021 |
| Merger or Acquisition (February 2021) | Merger or acquisition | 17 slides | Feb 3, 2021 |
| Technical Presentation (2020) | Technical | 7 slides | 2020 |
| Investor Presentation (October 2019) | Investor deck | 17 slides | Oct 22, 2019 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.1M | 445.8M | 361.1M | 296.5M | 219.5M | 117.5M | 120.4M | 92.0M | 72.0M | 65.1M |
| Cost of revenue | 157.1M | 147.6M | 112.9M | 101.6M | 74.4M | 41.5M | 36.1M | 33.1M | 28.2M | 25.5M |
| Gross profit | 362.5M | 298.1M | 229.7M | 175.7M | 145.1M | 76.0M | 83.8M | 58.9M | 43.8M | 39.6M |
| Research and development | 70.8M | 69.3M | 57.3M | 40.6M | 29.8M | 17.2M | 14.9M | 14.8M | 13.9M | 15.3M |
| Selling, general and administrative | 110.8M | 178.3M | 157.6M | 76.5M | 101.4M | 36.7M | 29.0M | 24.0M | 23.1M | 23.8M |
| Operating income | 57.8M | 16.1M | -85.8M | -41.1M | -81.9M | -35.4M | -15.1M | -22.2M | -26.5M | -28.8M |
| Depreciation and amortization | 21.4M | 23.5M | 27.2M | 25.9M | 19.6M | 7.94M | 4.12M | 3.92M | 3.84M | 3.51M |
| EBITDA | 79.2M | 39.6M | -58.6M | -15.2M | -62.3M | -27.4M | -11.0M | -18.3M | -22.7M | -25.3M |
| Interest expense | 1.00K | 2.00K | 15.0K | 198.0K | 241.0K | 229.0K | 677.0K | 1.96M | 4.94M | 2.76M |
| Income before tax | 68.2M | 25.7M | -76.6M | -36.4M | -81.6M | -34.9M | -12.6M | -23.0M | -31.0M | -31.4M |
| Income tax | 1.85M | 1.61M | -2.21M | 133.0K | -6.09M | 0 | 0 | 0 | 0 | 0 |
| Net income | 66.4M | 24.1M | -74.4M | -36.6M | -75.6M | -34.9M | -12.6M | -23.0M | -31.0M | -31.4M |
| Earnings per share, basic | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 |
| Earnings per share, diluted | 0.82 | 0.31 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 362.6M | 239.1M | 216.5M | 154.2M | 173.2M | 349.4M | 159.3M | 78.0M | 33.9M | 59.2M |
| Short-term investments | 50.3M | 50.4M | 0 | 24.6M | 3.96M | 0 | 120.0K | |||
| Receivables | 44.7M | 46.5M | 40.4M | 44.0M | 41.5M | 18.5M | 19.3M | 13.2M | 12.7M | 8.76M |
| Inventory | 20.5M | 21.8M | 16.1M | 14.3M | 11.2M | 4.66M | 6.81M | 3.40M | 5.32M | 3.48M |
| Current assets | 488.4M | 372.3M | 285.6M | 248.6M | 243.1M | 375.7M | 187.7M | 97.0M | 53.9M | 73.6M |
| Property, plant and equipment | 17.7M | 15.1M | 8.99M | 8.93M | 8.94M | 9.69M | 11.5M | |||
| Goodwill | 767.2M | 745.8M | 703.0M | 695.9M | 707.9M | 2.73M | 2.73M | 1.06M | 1.06M | 1.06M |
| Total assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B | 457.2M | 275.2M | 120.6M | 78.7M | 101.0M |
| Accounts payable | 4.59M | 8.63M | 12.9M | 11.9M | 12.4M | 3.12M | 2.33M | 2.52M | 3.85M | 2.42M |
| Current liabilities | 59.9M | 78.6M | 61.2M | 62.6M | 64.2M | 16.8M | 17.5M | 13.1M | 12.0M | 11.5M |
| Long-term debt | 0 | 810.0K | 694.0K | 23.9M | 24.9M | 24.9M | ||||
| Total debt | 39.7M | 50.7M | 12.6M | 0 | 1.13M | 810.0K | 694.0K | 25.3M | 24.9M | 24.9M |
| Total liabilities | 96.4M | 124.1M | 70.8M | 81.2M | 91.3M | 35.9M | 35.8M | 40.9M | 41.4M | 41.5M |
| Shareholders' equity | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B | 421.2M | 239.5M | 79.8M | 37.2M | 59.6M |
| Shares outstanding | 79.4M | 77.8M | 73.3M | 72.0M | 71.1M | 58.2M | 49.6M | 40.9M | 33.8M | 33.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 136.3M | 75.1M | 44.2M | 7.54M | -31.6M | -9.71M | -3.23M | -13.5M | -23.9M | -28.0M |
| Capital spending | -9.68M | -11.3M | -9.96M | -8.55M | -5.38M | -2.84M | -2.76M | -1.87M | -1.75M | -4.21M |
| Free cash flow | 126.6M | 63.8M | 34.3M | -1.01M | -37.0M | -12.5M | -5.99M | -15.4M | -25.7M | -32.2M |
| Cash from investing | -9.21M | -56.3M | 15.1M | -29.4M | -739.2M | -3.84M | -42.7M | -1.87M | -1.31M | -4.21M |
| Cash from financing | -4.22M | 4.90M | 2.84M | 3.49M | 596.3M | 203.6M | 127.3M | 59.5M | -218.0K | 52.3M |
| Dividends paid | -3.17M | -3.85M | -977.0K | 0 | 0 | |||||
| Share buybacks | -6.74M | -3.17M | -9.03M | -3.85M | -977.0K | -30.0K | 2.10M | 33.2M | ||
| Change in cash | 123.6M | 23.3M | 62.3M | -18.9M | -176.0M | 190.0M | 81.3M | 44.1M | -25.4M | 20.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 31, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 25, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 17, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Veracyte, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 80,695,480
- Fully diluted
- 80,695,480
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 80,695,480 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 80,695,480 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jesse I Treu Other companies: CoLucid Pharmaceuticals Inc (Director · May 5, 2015 – May 11, 2015 · Past); Aldeyra Therapeutics, Inc. (Director · May 1, 2014 – Jun 9, 2020 · Past); Tandem Diabetes Care, Inc. (Director · Nov 13, 2013 – Nov 15, 2016 · Past); Tobira Therapeutics Inc (Director · Aug 21, 2013 – Jan 1, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Mar 3, 2010 – Jun 9, 2010 · Past) | Director · Oct 29, 2013 – Feb 28, 2019 · Past |
| Evan Jones Other companies: CapForce Inc. (Director · May 4, 2015 – May 17, 2021 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); CAS Medical Systems Inc (Director · Jun 20, 2012 – Jun 24, 2013 · Past); Standard BioTools Inc. (Director · Dec 12, 2011 – Jul 31, 2017 · Past) | Board Member · Since at least Oct 29, 2013 |
| Karin Eastham Other companies: Personalis, Inc. (Chair · Since at least Sep 9, 2019); Nektar Therapeutics (Director · Sep 27, 2018 – Sep 16, 2022 · Past); Geron Corporation (Director · May 17, 2016 – Jan 13, 2023 · Past); Illumina, Inc. (Director · May 17, 2016 – May 28, 2019 · Past) | Board Member · Since at least Jun 20, 2016 |
| Rebecca Chambers Other companies: Alamar Biosciences, Inc. (Director · Since at least Apr 16, 2026); Inari Medical Inc (Director · Jun 21, 2021 – Feb 19, 2025 · Past); Outset Medical, Inc. (Chief Financial Officer · Sep 14, 2020 – Jun 24, 2021 · Past) | Chief Financial Officer · Since at least Jul 19, 2021 |
| Brent Shafer Other companies: Tactile Systems Technology, Inc. (Director · Since at least Nov 5, 2026); Baxter International Inc. (Chair of the Board, Former Chair · Since at least May 4, 2026) | Board Member · Since at least Nov 6, 2024 |
| David Brent Shafer Other companies: Tactile Systems Technology, Inc. (Director · Since at least May 6, 2026); Baxter International Inc. (Director · Since at least May 5, 2026) | Director · Since at least Jun 11, 2026 |
| John L Bishop Other companies: Cepheid (Chairman of the Board and CEO, Director · Feb 26, 2009 – Nov 4, 2016 · Past); Conceptus Inc (Director · Feb 25, 2009 – Jun 5, 2013 · Past) | Director · Dec 1, 2014 – Jul 17, 2023 · Past |
| Keith Kennedy Other companies: CareDx, Inc. (Chief Financial Officer and Chief Operating Officer · Since at least Sep 12, 2024); MCG Capital Corp (President and CEO, Director · Aug 14, 2015 – Aug 18, 2015 · Past) | COO / CFO · Dec 6, 2016 – Mar 2, 2021 · Past |
| Beverly Jane Alley Other companies: MCG Capital Corp (CFO · Mar 15, 2012 – Aug 18, 2015 · Past) | VP, Corporate Controller · Apr 1, 2021 – May 17, 2021 · Past |
| Bonnie H Anderson Other companies: Bruker Corporation (Director · Since at least Jan 5, 2023) | Director · May 1, 2022 – Jun 2, 2023 · Past |
All 25 people
| Person | Seat |
|---|---|
| Christopher Hall Other companies: Personalis, Inc. (Director · Since at least Dec 31, 2022) | President and COO · Jul 22, 2015 – Jun 3, 2019 · Past |
| Kevin Haas Other companies: Myriad Genetics, Inc. (Chief Technology Officer · Since at least Feb 2, 2026) | Chief Development and Technology Officer · Since at least Mar 16, 2026 |
| Marc A. Stapley Other companies: Glaukos Corporation (Director · Since at least May 30, 2019) | Chief Executive Officer, Director · Since at least Jun 1, 2021 |
| Phillip G Febbo Other companies: Illumina, Inc. (SVP Chief Medical Officer · Apr 5, 2022 – Mar 1, 2023 · Past) | Chief Scientific & Med Officer · Since at least Oct 2, 2023 |
| Robert S. Epstein Other companies: Fate Therapeutics, Inc. (Board Member · Since at least May 5, 2026) | Director · Since at least May 20, 2026 |
| Annie McGuire | EVP, General Counsel · Since at least Feb 28, 2022 |
| Eliav Barr | Board Member · Since at least Jun 15, 2026 |
| Giulia C Kennedy | Chief Scientific & Med Officer · Feb 21, 2019 – Dec 6, 2022 · Past |
| Jens Holstein | Board Member · Since at least Jun 18, 2025 |
| John Leite | Global Chief Commercial Off · Since at least Sep 1, 2023 |
| Jonathan Wygant | VP, Chief Accounting Officer · Since at least Aug 5, 2022 |
| Marc Stapely | Until Sep 4, 2026 · Past |
| Muna Bhanji | Board Member · Since at least Oct 20, 2026 |
| Thomas F Miller | Director · Since at least Sep 3, 2024 |
| Tom Miller | Director · Since at least Nov 6, 2024 |
Log in to ask 6ix AI your own questions about Veracyte, Inc.